Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
65.66
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
497
Open
65.66
Bid (Size)
64.64 (1)
Ask (Size)
66.25 (2)
Prev. Close
65.66
Today's Range
65.66 - 65.66
52wk Range
61.15 - 99.25
Shares Outstanding
183,352,255
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Latest Analyst Ratings For Biomarin Pharmaceutical
December 12, 2024
Via
Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
December 02, 2024
Despite its growth, NASDAQ:BMRN remains within the realm of affordability.
Via
Chartmill
Performance
YTD
-33.03%
-33.03%
1 Month
+2.18%
+2.18%
3 Month
-5.02%
-5.02%
6 Month
-22.88%
-22.88%
1 Year
-31.93%
-31.93%
More News
Read More
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
November 22, 2024
Via
Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
November 22, 2024
Via
MarketBeat
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
November 15, 2024
Via
Benzinga
NASDAQ:BMRN stands out as a growth opportunity that won't break the bank.
November 11, 2024
Via
Chartmill
Peering Into Biomarin Pharmaceutical's Recent Short Interest
November 06, 2024
Via
Benzinga
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
October 30, 2024
Via
Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
October 28, 2024
Via
Benzinga
CAMP4 Analyst Highlights Rare Disease Platform Potential
November 05, 2024
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
October 30, 2024
Via
Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 24, 2024
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
October 18, 2024
Via
Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
October 15, 2024
Via
Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
October 04, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
September 23, 2024
Via
Benzinga
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
October 16, 2024
Via
Chartmill
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
Via
Benzinga
3 Oversold Stocks with Big RSI Rebound Potential
October 03, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
September 26, 2024
Via
Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
September 25, 2024
Via
Benzinga
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
September 25, 2024
Via
Chartmill
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
Via
Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
September 17, 2024
Via
Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
September 16, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.